WEBULL
WebtradeDownload

Zenas BioPharma (ZBIO) Could Be 44% Undervalued As New Shelf Filings Raise Dilution Questions

Simply Wall St · 1d ago

Why Zenas BioPharma Filed New Shelf Registrations

Zenas BioPharma (ZBIO) recently filed two shelf registration statements that together cover up to US$244.69 million of common stock, including 7,600,000 shares tied partly to an ESOP related offering.

These filings give the biopharma group flexibility to issue new equity over time. Investors often watch such moves closely because fresh capital access can also raise questions about potential dilution and funding priorities.

Zenas BioPharma’s US$33.05 share price sits on top of a 90 day share price return of 51.61%, while total shareholder return over the past year is 74.31%, showing momentum that has built even as the year to date share price return has slipped 4.20%.

Scan how Zenas BioPharma compares to other high-growth healthcare names eyeing fresh equity access by reviewing our curated list of 37 healthcare AI stocks.

Bulls see Zenas BioPharma using the new shelf capacity to fund a growing immunology pipeline, while bears focus on dilution risk and ongoing losses. Which story does the current valuation lean toward?

Most Popular Narrative: 44% Undervalued

Against Zenas BioPharma’s last close at $33.05, the most followed narrative pegs fair value at $59, which points to a wide valuation gap that bullish investors are trying to explain through pipeline and revenue assumptions.

A broad pipeline that includes the oral IL-17 inhibitor ZB021 and the brain penetrant TYK2 inhibitor ZB022, combined with a cash balance of about US$674 million and additional accessible funding, allows Zenas BioPharma to advance multiple programs toward proof of concept without near term equity raises, which can influence future earnings per share through both potential new revenue lines and reduced financing costs.

See why 0 investors see Zenas BioPharma as 44% undervalued.

Result: Fair Value of $59 (UNDERVALUED)

Still, rising quarterly losses and reliance on external financing mean Zenas BioPharma’s growth plans depend on continued capital access and timely progress for obexelimab.

Find out about the key risks to this Zenas BioPharma narrative.

Next Steps

Mixed signals around Zenas BioPharma can make the story feel urgent, so consider reviewing the 1 key reward and 3 important warning signs promptly and weighing both sides for yourself.

Looking for more Zenas BioPharma style ideas?

If Zenas BioPharma has your attention, do not stop with a single ticker. Broaden your watchlist now so you are not late to the next setup.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.